The Clinical and Administrative Core (Core D) is designed to: 1) Facilitate interactions between Projects and Cores;2) Provide administrative support for: a) GTRP applications and interactions (Clinical Grade Vector manufacture, Biodistribution &Toxicology Studies);and b) manage IND submissions (Project 1, and perhaps Project 2). Organizational and Administrative Structure. The Principal Investigator of the proposed Program, Dr. H. Kirk Hammond, will be responsible for all operations and policy decisions of the program. He will report to and be assisted by several Program Committees including: a) Local Advisory Committee. This Committee will be comprised of the Project Leaders of all the research components (Drs. Hammond, Roth, and Dillmann). The committee will meet quarterly to identify and solve problems related to general programmatic issues and evaluate progress toward the program's goals;b) External Advisory Committee. This Committee consists of three basic and clinical research investigators with expertise directly relevant to gene transfer, cardiovascular physiology and heart failure. The committee will meet in La Jolla annually to confer with the Principal Investigator and the participating investigators in the program. These clinicians and scientists will play an important advisory role in the implementation, oversight, and data assessment in the overall Program;c) Data and Safety Monitoring Board (DSMB). The NHLBI DSMB will assess any clinical trials that are initiated in the tenure of the proposed renewal Program, as mandated by the NIH. The day-to-day operations of the program including program development and oversight will be coordinated through Dr. Hammond. The local site administrative personnel will include an experienced and senior program Administrative Assistant (Ms. Eileen D'Souza).

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Veterans Medical Research Fdn/San Diego
San Diego
United States
Zip Code
Pandey, Amit K; Penny, William F; Bhargava, Valmik et al. (2016) Clinical Evaluation of Heart Failure: Agreement among Tests. PLoS One 11:e0161536
Gao, Mei Hua; Giamouridis, Dimosthenis; Lai, N Chin et al. (2016) One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance. JCI Insight 1:e88322
Schilling, Jan M; Horikawa, Yousuke T; Zemljic-Harpf, Alice E et al. (2016) Electrophysiology and metabolism of caveolin-3-overexpressing mice. Basic Res Cardiol 111:28
Cividini, Federico; Scott, Brian T; Dai, Anzhi et al. (2016) O-GlcNAcylation of 8-Oxoguanine DNA Glycosylase (Ogg1) Impairs Oxidative Mitochondrial DNA Lesion Repair in Diabetic Hearts. J Biol Chem 291:26515-26528
See Hoe, Louise E; Schilling, Jan M; Busija, Anna R et al. (2016) Chronic β1-adrenoceptor blockade impairs ischaemic tolerance and preconditioning in murine myocardium. Eur J Pharmacol 789:1-7
Tran, Chinh; Stary, Creed M; Schilling, Jan M et al. (2015) Role of caveolin-3 in lymphocyte activation. Life Sci 121:35-9
Lai, N Chin; Gao, Mei Hua; Giamouridis, Dimosthenis et al. (2015) Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice. Hum Gene Ther 26:347-56
Schilling, Jan M; Roth, David M; Patel, Hemal H (2015) Caveolins in cardioprotection - translatability and mechanisms. Br J Pharmacol 172:2114-25
Sun, Junhui; Nguyen, Tiffany; Aponte, Angel M et al. (2015) Ischaemic preconditioning preferentially increases protein S-nitrosylation in subsarcolemmal mitochondria. Cardiovasc Res 106:227-36
Markandeya, Yogananda S; Phelan, Laura J; Woon, Marites T et al. (2015) Caveolin-3 Overexpression Attenuates Cardiac Hypertrophy via Inhibition of T-type Ca2+ Current Modulated by Protein Kinase Cα in Cardiomyocytes. J Biol Chem 290:22085-100

Showing the most recent 10 out of 75 publications